Zacks: Analysts Anticipate Lipocine Inc (LPCN) to Announce -$0.15 Earnings Per Share

Equities analysts forecast that Lipocine Inc (NASDAQ:LPCN) will post earnings of ($0.15) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Lipocine’s earnings. Lipocine posted earnings of ($0.25) per share in the same quarter last year, which indicates a positive year over year growth rate of 40%. The business is expected to report its next earnings report on Monday, March 11th.

According to Zacks, analysts expect that Lipocine will report full year earnings of ($0.53) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.49). For the next year, analysts expect that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.38) to ($0.42). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Lipocine.

Lipocine (NASDAQ:LPCN) last released its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.12.

A number of equities research analysts have recently issued reports on LPCN shares. HC Wainwright set a $3.00 price objective on Lipocine and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity reiterated a “hold” rating and issued a $1.50 price target on shares of Lipocine in a research note on Friday, August 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $6.38.

Shares of NASDAQ:LPCN opened at $1.41 on Friday. Lipocine has a 12-month low of $1.03 and a 12-month high of $3.74. The company has a market cap of $30.26 million, a PE ratio of -1.34 and a beta of 0.41. The company has a debt-to-equity ratio of 0.67, a current ratio of 7.40 and a quick ratio of 7.40.

An institutional investor recently raised its position in Lipocine stock. JPMorgan Chase & Co. boosted its stake in Lipocine Inc (NASDAQ:LPCN) by 145.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,429 shares of the specialty pharmaceutical company’s stock after purchasing an additional 56,606 shares during the period. JPMorgan Chase & Co. owned about 0.44% of Lipocine worth $132,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.33% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Recommended Story: Institutional Investors

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with's FREE daily email newsletter.

Leave a Reply